Protara Therapeutics Stock Investor Sentiment
TARA Stock | USD 3.04 0.10 3.40% |
About 57% of all Protara Therapeutics' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Protara Therapeutics suggests that some traders are interested. The current market sentiment, together with Protara Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Protara Therapeutics stock news signals to limit their universe of possible portfolio assets.
Protara |
Protara Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Protara Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Protara Therapeutics that are available to investors today. That information is available publicly through Protara media outlets and privately through word of mouth or via Protara internal channels. However, regardless of the origin, that massive amount of Protara data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Protara Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Protara Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Protara Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Protara Therapeutics alpha.
Protara Therapeutics Performance against Dow Jones
Price Growth (%) |
Timeline |
1 | Insider Trading | 09/05/2024 |
2 | Disposition of 1900 shares by Opaleye Management Inc. of Protara Therapeutics at 1.8947 subject to Rule 16b-3 | 09/09/2024 |
3 | Disposition of 1500 shares by Opaleye Management Inc. of Protara Therapeutics at 1.769 subject to Rule 16b-3 | 09/10/2024 |
4 | Disposition of 1600 shares by Opaleye Management Inc. of Protara Therapeutics at 1.7141 subject to Rule 16b-3 | 09/11/2024 |
5 | Disposition of 6500 shares by Opaleye Management Inc. of Protara Therapeutics at 1.7089 subject to Rule 16b-3 | 09/12/2024 |
6 | Dockworkers Reach Deal To End Massive East Coast Strike | 10/04/2024 |
7 | Disposition of 3500 shares by Opaleye Management Inc. of Protara Therapeutics at 2.4419 subject to Rule 16b-3 | 10/30/2024 |
8 | Protara Therapeutics Stock Price Up 0.8 percent Still a Buy | 11/08/2024 |
9 | Protara Therapeutics Q3 Earnings Snapshot | 11/12/2024 |
10 | Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of U... | 11/15/2024 |
11 | Disposition of 500 shares by Opaleye Management Inc. of Protara Therapeutics at 3.0021 subject to Rule 16b-3 | 11/22/2024 |
Complementary Tools for Protara Stock analysis
When running Protara Therapeutics' price analysis, check to measure Protara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protara Therapeutics is operating at the current time. Most of Protara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protara Therapeutics' price. Additionally, you may evaluate how the addition of Protara Therapeutics to your portfolios can decrease your overall portfolio volatility.
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Fundamental Analysis View fundamental data based on most recent published financial statements |